Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883381 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL20444711 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL1639395 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL23425431 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL16359926 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL23679991 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL17972356 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL17976623 | 1.00 | HINT1 (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL28911220 | 0.92 | HINT1 (0.60) | HINT1HPGDNT5EGSK3ARPS6KA3 | |
| SCHEMBL26515 | 0.92 | HPGD (0.61) | HINT1HPGDNT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025229572-A1 | EPSTEIN-BARR VIRUS ANTIGEN-ENCODING MESSENGER RIBONUCLEIC ACID AND ANTIGEN PROTEIN VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-11-06 | — | — | WO | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| CN-117925755-A | Synthesis method of nucleoside intermediate 2' -O-methyl guanosine | 康羽生命科学技术(苏州)有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116144771-A | Molecular parting gene group of hepatocellular carcinoma, diagnostic product and application | 南京鼓楼医院 | 2023-05-23 | — | — | CN | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| EP-2010659-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | Epicentre Technologies (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120863-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES (US) | 2007-10-25 | — | — | WO | claimed |
| EP-4717779-A2 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TriLink BioTechnologies, LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4276189-B1 | INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4424835-B1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025229572-A1 | EPSTEIN-BARR VIRUS ANTIGEN-ENCODING MESSENGER RIBONUCLEIC ACID AND ANTIGEN PROTEIN VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-11-06 | — | — | WO | disclosed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-1223173-A2 | Novel 2'-O-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof | ISIS PHARMACEUTICALS, INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-6110901-A | 3'-DEOXYRIBOCYTOSINE, 3'-DEOXYRIBOURACIL, AND/OR 3'-DEOXYRIBOGUANINE | AMERICAN CYANAMID COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-5914396-A | 2'-O-modified nucleosides and phosphoramidites | ISIS PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5506351-A | Process for the preparation of 2'-O-alkyl guanosine and related compounds | ISIS PHARMACEUTICALS (US) | 1996-04-09 | — | — | US | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | HINT1 4350/4885HPGD 3841/4885NT5E 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.